Yahoo · Sep 30, 2026
Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients
Eupraxia Pharmaceuticals (EPRX.TO), up 7.9% to a record high on last look, said on Wednesday updated
EP
NASDAQ · EPRX
Eupraxia Pharmaceuticals Inc.
Healthcare · Biotechnology
$7.74
Down-$0.01 (-0.06%)
Updated Oct 7, 2026, 7:04 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 216.11M
- P/E ratio
- -7.17
- Dividend yield
- 0.00%
- 52-week range
- $5.25 – $9.32
- Volume
- 1.64M
- Avg. volume
- 144.03K
Price performance · EPRX
EPRX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
EPRX closed at $7.74 after 21 trading sessions, down 6.18% for the selected period.
- Last close
- $7.74
- Period change
- -6.18%
- Period low
- $7.24
- Period high
- $9.10
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $7.81 | $8.07 | $7.67 | $7.74 | 1.64M |
| Oct 5, 2026 | $7.20 | $7.93 | $7.07 | $7.745 | 1.77M |
| Oct 2, 2026 | $8.00 | $8.09 | $7.19 | $7.24 | 1.71M |
| Oct 1, 2026 | $8.91 | $9.12 | $7.68 | $7.83 | 3.65M |
| Sep 30, 2026 | $8.33 | $9.21 | $8.125 | $9.10 | 1.28M |
| Sep 29, 2026 | $8.16 | $8.46 | $8.08 | $8.305 | 645.11K |
| Sep 28, 2026 | $7.84 | $8.22 | $7.84 | $8.21 | 369.12K |
| Sep 25, 2026 | $8.19 | $8.30 | $7.86 | $8.01 | 1.31M |
| Sep 24, 2026 | $8.35 | $8.35 | $7.841 | $8.16 | 452.92K |
| Sep 23, 2026 | $8.55 | $8.605 | $7.98 | $8.14 | 662.59K |
| Sep 22, 2026 | $8.77 | $8.77 | $8.39 | $8.58 | 781.67K |
| Sep 21, 2026 | $8.73 | $8.77 | $8.51 | $8.64 | 314.19K |
| Sep 18, 2026 | $8.37 | $8.715 | $8.37 | $8.58 | 555.04K |
| Sep 17, 2026 | $8.30 | $8.425 | $8.2591 | $8.38 | 257.87K |
| Sep 16, 2026 | $8.12 | $8.25 | $8.00 | $8.09 | 197.6K |
| Sep 15, 2026 | $8.05 | $8.14 | $7.93 | $8.11 | 197.83K |
| Sep 14, 2026 | $8.32 | $8.365 | $8.00 | $8.07 | 432.12K |
| Sep 11, 2026 | $8.14 | $8.49 | $8.11 | $8.42 | 492.93K |
| Sep 10, 2026 | $7.95 | $8.30 | $7.8402 | $8.02 | 260.91K |
| Sep 9, 2026 | $8.18 | $8.33 | $8.00 | $8.08 | 186.53K |
| Sep 8, 2026 | $8.42 | $8.60 | $8.22 | $8.25 | 375.21K |
Latest EPRX news
The latest Smart Investors Daily articles mentioning EPRX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
EPRX research
Overview
Company profile and research snapshot.
Company profile
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | RAYMOND JAMES LTD. | Strong Buy | — |
| Aug 27, 2026 | WILLIAM BLAIR & COMPANY | Outperform | — |
| Aug 12, 2026 | RESEARCH CAPITAL CORPORATION | Buy | — |
| May 22, 2026 | RAYMOND JAMES LTD. | Strong Buy | — |
| May 21, 2026 | RAYMOND JAMES LTD. | Strong Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 30, 2026
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
The highest dose group of EP-104GI (Cohort 9) demonstrated durability of symptom responses out to 52 weeks, with 66% of patients (2 of 3) maintaining clinical remission1The second highest dose group of EP-104GI (Cohort 8b) continued to show meaningful histologic reduction in inflammation and fibrosis with Stage –0.26 and Grade –0.27 in EoEHSS at 36 weeksThe Cohort 8b and Cohort 9 responses are consistent with clinical and histologic responses seen across all cohorts analyzed to date; in total, 9
Benzinga · Sep 24, 2026
Wedbush Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17
Wedbush analyst Martin Fan initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
Yahoo · Sep 12, 2026
Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice
On August 13, Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) released new data from its Phase 1b/2a RESOLVE trial showing that odynophagia, the medical term for painful swallowing, faded dramatically in patients treated with its lead drug candidate EP-104GI. In the highest-dose cohorts, moderate to severe odynophagia fell from 62% of patients at baseline to just 25% by […]
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
